In this article, we take a look at the 12 Best 52-Week High Stocks to Buy Right Now.
All three major US indices are poised to end the year near record highs in what is turning out to be a blockbuster year for stocks. Investors moving past concerns about the state of the economy amid tariffs and the trade war, exacerbated by monetary policy uncertainties, have seen equities rally to record highs.
The US Federal Reserve, embarking on an interest rate-cutting spree, has emerged as an essential catalyst, supporting equities. The easier monetary policy, at a time when sky-high valuations are arousing concerns, is also supporting bulls in the market.
“The Federal Reserve is cutting interest rates during a time when stocks are at record highs and the economy is still growing. This dynamic is bullish for stocks. Big tech stocks tend to outperform during lower interest-rate environments, and financials may see a boost from additional M&A and mortgage activity that may come about from lower rates,” said Robert Schein at Blanke Schein Wealth. Management.
With markets at all-time highs, there is growing concern of a potential bubble amid swollen valuations. Nevertheless, it’s becoming increasingly clear that solid financial results and a resilient US economy will support the elevated valuations.
“Investors have happily bought every dip, largely thanks to AI-driven enthusiasm and consistently strong results from big tech,” said Fawad Razaqzada at City Index and Forex.com. “The concern is that if tech momentum cools, the rest of the market may struggle to justify current valuations.”
Likewise, Ulrike Hoffmann-Burchardi at UBS Global Wealth Management expects lower interest rates, robust earnings growth, and AI tailwinds to offer much-needed support for global equities heading into year-end. With that in mind, let’s take a look at some of the Best 52-Week High Stocks to Buy Right Now.
Our Methodology
To compile our list of the 12 Best 52‑Week High Stocks to Buy Right Now, we used the Finviz stock screener to identify companies trading within 0%–10% of their 52‑week highs and showing year‑to‑date gains of more than 30%. These stocks are also favored by elite hedge funds and offer upside potential of over 20%. We then ranked them in ascending order based on the number of hedge funds holding positions as of Q3 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research shows we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).
Best 52-Week High Stocks to Buy Right Now
12. Copa Holdings, S.A. (NYSE:CPA)
52 Week Range: $82.54 – $130.00
Current Share Price as of December 4: $118.24
Year to date Gain: 39.81%
Stock Upside Potential: 33.53%
Number of Hedge Fund Holders: 21
Copa Holdings, S.A. (NYSE:CPA) is one of the best 52-week high stocks to buy right now. Copa Holdings, S.A. (NYSE:CPA) has a strong Buy consensus rating from 5 Wall Street analysts, including 5 Buy ratings. The average price target on the stock is $161, implying 33.53% upside potential from the current level of $120.57 a share.
The positive stance on Wall Street coincides with the company’s delivery of another strong quarter on November 20, affirming the strength of its business model and competitive advantage in the Latin American aviation market. Disciplined cost management and healthy demand across networks also helped the company achieve industry-leading operating and net margins of 23.2% and 19%.
Operating revenues increased 6.8% in the third quarter to $913.1 million, attributed to 5.8% capacity growth. Passenger revenue was up 5.2% and cargo and mail revenue increased 21.4%. Earnings per share came in at $4.20, compared to the $4.04 forecast.
Meanwhile, on November 24, Barclay’s analyst Pablo Monsivais reiterated a Buy rating on the stock and set a $150 price target.
Copa Holdings, S.A. (NYSE:CPA) is a Panamanian company that provides passenger and cargo air transportation services throughout the Americas through its operating subsidiaries, Copa Airlines, Copa Airlines Colombia, and Wingo.
11. Immunocore Holdings plc (NASDAQ:IMCR)
52 Week Range: $23.15 – $40.71
Current Share Price as of December 4: $40.70
Year to date Gain: 43.84%
Stock Upside Potential: 62.25%
Number of Hedge Fund Holders: 25
Immunocore Holdings PLC (NASDAQ:IMCR) is one of the best 52-week high stocks to buy right now. Immunocore Holdings PLC (NASDAQ:IMCR) commands a consensus Moderate Buy rating from 9 Wall Street analysts, comprising 6 Buy and 3 Hold ratings. The average price target on the stock is $65.25, implying 62.25% upside potential.
On November 21, H.C. Wainwright’s Patrick Trucchio reaffirmed a Buy rating on Immunocore Holdings with a $100 price target, following TD Cowen’s Tyler Van Buren, who also issued a Buy on November 13.
Just days earlier, on November 19 at the Jefferies London Healthcare Conference 2025, Immunocore Holdings showcased strategic advancements that affirmed significant pipeline development and strong commercial performance. It has made significant progress on KIMMTRAK development, currently in Phase 3 trials in cutaneous melanoma.
The company is working on PRAME Bispecific, currently in Phase 3 trials as a potential treatment option for multiple cancers, with data expected in the first half of next year. In addition, it is pursuing cures for HIV and HBV. The pipeline development is supported by a robust cash position of about $892 million as of the end of the third quarter.
Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company that develops TCR bispecific immunotherapies to treat cancer, infectious diseases, and autoimmune conditions. Using its proprietary ImmTAX technology, the company designs therapies that harness the immune system by either activating it to destroy diseased cells or dampening it to reduce autoimmune responses.
10. Apogee Therapeutics Inc. (NASDAQ:APGE)
52 Week Range: $26.20 – $77.00
Current Share Price as of December 4: $75.43
Year to date Gain: 60.13%
Stock Upside Potential: 27.43%
Number of Hedge Fund Holders: 30
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best 52-week high stocks to buy right now. On December 3, TD Cowen’s Tyler Van Buren reiterated a Buy rating on Apogee Therapeutics Inc. (NASDAQ:APGE). Earlier, on November 13, Canaccord Genuity’s Edward Nash reiterated a Buy rating on Apogee Therapeutics with a $89 price target, citing its strong financial position, cash reserves from a recent equity raise, and a promising pipeline. Key data readouts in 2026—including asthma and atopic dermatitis trials, could bolster its market standing, while the potential dosing advantage of APG777 over Dupixent adds to the positive outlook.
On November 10, Apogee Therapeutics reported that its antibody APG333 showed a 55‑day half‑life in Phase 1 trials, supporting potential quarterly or semi‑annual dosing. Clinical trials have shown that APG333 can suppress key biomarkers for up to six months on a single dose. It stands out in its ability to target thymic stromal lymphopoietin. In trials, the drug was well-tolerated with mild side effects.
The positive results affirm the company’s prospects in delivering durable activity, which may enable less frequent dosing compared to available agents.
“The extended PK and favorable tolerability profile of APG333 underscores Apogee’s potential to advance a quarterly or better dosing combination of APG777 and APG333, designed to address key drivers of respiratory diseases more broadly than a monotherapy,” said Michael Henderson, M.D., Chief Executive Officer of Apogee.
Apogee Therapeutics Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company that develops novel biologic therapies for inflammatory and immunological diseases. The company focuses on conditions such as atopic dermatitis, asthma, and COPD by advancing antibody-based drugs to improve efficacy and enable more convenient dosing.
9. Orla Mining Ltd. (NYSE:ORLA)
52 Week Range: $4.90 – $14.36
Current Share Price as of December 4: $12.86
Year to date Gain: 129.25%
Stock Upside Potential: 31.40%
Number of Hedge Fund Holders: 33
Orla Mining Ltd (NYSE:ORLA) is one of the best 52-week high stocks to buy right now. Orla Mining Ltd (NYSE:ORLA) commands a strong Buy rating from 6 Wall Street analysts. The average price target for the stock is $17.54, implying 31.40% upside from $13.35 a share.
On November 11, Chief Executive Officer Jason Simpson confirmed that the company had a strong third quarter, achieving a record free cash flow of $93 million. The bolstered balance sheet positions the company to self-finance the next stage of growth at the South Railroad project. Gold production in the quarter rose to 79,645 ounces.
Likewise, the company sold 78,857 ounces of gold and generated $257 million in revenue. Its net income totaled $49.3 million or $0.15 a share. Adjusted earnings totaled $73 million or $0.22 a share. Following the strong third-quarter results, BMO Capital analyst Andrew Mikitchook reiterated a Buy rating on the stock. Stifel Nicolaus analyst Ingrid Rico also maintains a Buy rating on the stock.
Orla Mining Ltd. (NYSE:ORLA) acquires, develops, and operates mineral properties, with a focus on gold and silver. It owns and operates the Camino Rojo gold and silver mine in Mexico, is developing the South Railroad project in Nevada, and recently acquired the Musselwhite gold mine in Ontario, Canada.
